{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T01:26:06Z","timestamp":1780449966831,"version":"3.54.1"},"update-to":[{"DOI":"10.1002\/14651858.cd003993.pub2","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2011,2,16]],"date-time":"2011-02-16T00:00:00Z","timestamp":1297814400000}}],"reference-count":79,"publisher":"Wiley","issue":"5","content-domain":{"domain":["wiley.com","cochranelibrary.com"],"crossmark-restriction":true},"short-container-title":[],"DOI":"10.1002\/14651858.cd003993.pub3","type":"journal-article","created":{"date-parts":[[2011,2,4]],"date-time":"2011-02-04T13:33:27Z","timestamp":1296826407000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Thymic peptides for treatment of cancer patients"],"prefix":"10.1002","volume":"2017","author":[{"given":"Elke","family":"Wolf","sequence":"first","affiliation":[{"name":"Klinikum Nord; Medizinische Klinik 5-Schwerpunkt Onkologie\/Haematologie; Prof.-Ernst-Nathan-Str. 1 Nuernberg Germany 90340"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Milazzo","sequence":"additional","affiliation":[{"name":"Paracelsus Medical University, Klinikum Nuernberg; Department of Internal Medicine, Division of Oncology and Hematology; Prof.-Ernst-Nathan-Str. 1 Nuernberg Germany D-90419"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katja","family":"Boehm","sequence":"additional","affiliation":[{"name":"Klinikum Nord; Medizinische Klinik 5-Schwerpunkt Onkologie\/Haematologie; Prof.-Ernst-Nathan-Str. 1 Nuernberg Germany 90340"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcel","family":"Zwahlen","sequence":"additional","affiliation":[{"name":"University of Bern; Institute of Social and Preventive Medicine; Finkelhubelweg11 Bern Switzerland 3012"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Horneber","sequence":"additional","affiliation":[{"name":"Paracelsus Medical University, Klinikum Nuremberg; Department of Internal Medicine, Division of Oncology and Hematology; Prof.-Ernst-Nathan-Str. 1 Nuremberg Germany D-90419"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2011,2,16]]},"reference":[{"key":"10.1002\/14651858.CD003993.pub3-BIB0001|cit1","first-page":"67","article-title":"Chemioterapia versus chemioimmunoterapia con Timostimulina nei carcinomi avanzati del cavo orale: risultati clinici di uno studio randomizzato","volume":"78 Suppl 6","author":"Airoldi","year":"1987","journal-title":"Recenti Progressi in Medicina"},{"issue":"5","key":"10.1002\/14651858.CD003993.pub3-BIB0002|cit2","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1097\/00000421-198410000-00002","article-title":"Prospective evaluation of thymosin fraction V immunotherapy in patients with non-small cell lung cancer receiving vindesine, doxorubicin, and cisplatin (VAP) chemotherapy","volume":"7","author":"Bedikian","year":"1984","journal-title":"American Journal of Clinical Oncology"},{"issue":"7","key":"10.1002\/14651858.CD003993.pub3-BIB0003|cit3","first-page":"340","article-title":"[Thymostimulin as an adjuvant to antineoplastic chemotherapy. Experience with patients with myeloma and lymphoma]","volume":"183","author":"Canovas Fernandez","year":"1988","journal-title":"Revista Clinica Espanola"},{"issue":"2","key":"10.1002\/14651858.CD003993.pub3-BIB0004|cit4","first-page":"69","article-title":"[The use of thymostimulin in lymphoma and myeloma patients]","volume":"8","author":"Canovas Fernandez","year":"1991","journal-title":"Anales de Medicina Interna"},{"issue":"59","key":"10.1002\/14651858.CD003993.pub3-BIB0005|cit5","first-page":"1445","article-title":"Combination transcatheter hepatic arterial chemoembolization with thymosin alpha1 on recurrence prevention of hepatocellular carcinoma","volume":"51","author":"Cheng","year":"2004","journal-title":"Hepatogastroenterology"},{"issue":"11","key":"10.1002\/14651858.CD003993.pub3-BIB0006|cit6","first-page":"1787","article-title":"Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy","volume":"62","author":"Chretien","year":"1978","journal-title":"Cancer Treatment Reports"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0007|cit7","doi-asserted-by":"crossref","first-page":"1813","DOI":"10.1001\/jama.1979.03290430031019","article-title":"Thymosin fraction V and intensive combination chemotherapy","volume":"241","author":"Cohen","year":"1979","journal-title":"Journal of the American Medical Association"},{"issue":"3","key":"10.1002\/14651858.CD003993.pub3-BIB0008|cit8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1002\/1097-0142(197903)43:3<863::AID-CNCR2820430313>3.0.CO;2-5","article-title":"Thymosin immunotherapy in patients with small cell carcinoma of the lung: correlation of in vitro studies with clinical course","volume":"43","author":"Lipson","year":"1979","journal-title":"Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003993.pub3-BIB0009|cit9","first-page":"499","article-title":"Secondary immunodeficiency in advanced lung cancer: effects of chemotherapy plus thymostimulin in immunodepressed patients: updating results","volume":"6","author":"Giacco","year":"1984","journal-title":"International Journal of Tissue Reactions"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0010|cit10","first-page":"149","article-title":"Thymic factors in lung cancer","volume-title":"Thymic hormones in oncology","author":"Giacco","year":"1988"},{"issue":"6","key":"10.1002\/14651858.CD003993.pub3-BIB0011|cit11","first-page":"487","article-title":"[The effects of thymostimulin in a protocol of concurrent hyperfractionated carboplatin and irradiation]","volume":"48","author":"Serdio","year":"1997","journal-title":"Acta Otorrinolaringologica Espanola"},{"issue":"1","key":"10.1002\/14651858.CD003993.pub3-BIB0012|cit12","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1097\/00000421-199502000-00002","article-title":"Effects of thymostimulin with combination chemotherapy in patients with aggressive Non-Hodgkin lymphoma. A report from the Italian Lymphoma Study Group (GISL)","volume":"18","author":"Federico","year":"1995","journal-title":"American Journal of Clinical Oncology"},{"issue":"2B","key":"10.1002\/14651858.CD003993.pub3-BIB0013|cit13","first-page":"731","article-title":"A prospective randomized trial of thymopentin versus granulocyte-colony stimulating factor with or without thymopentin in the prevention of febrile episodes in cancer patients undergoing highly cytotoxic chemotherapy","volume":"14","author":"Gebbia","year":"1994","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0014|cit14","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1007\/s12072-009-9132-3","article-title":"A randomized controlled trial of thymalfasin plus transarterial chemoembolization for unresectable hepatocellular carcinoma","volume":"3","author":"Gish","year":"2009","journal-title":"Hepatology International"},{"issue":"7-8","key":"10.1002\/14651858.CD003993.pub3-BIB0015|cit15","first-page":"358","article-title":"[Efficacy and tolerability of thymopoietin in patients at risk of infection]","volume":"78","author":"GISOT (Gruppo Italiano di Studio Sugli Ormoni Timici)","year":"1987","journal-title":"Recenti Progressi in Medicina"},{"issue":"2","key":"10.1002\/14651858.CD003993.pub3-BIB0016|cit16","doi-asserted-by":"crossref","first-page":"79","DOI":"10.2165\/00044011-199509020-00004","article-title":"Thymostimulin in association with chemotherapy in breast cancer patients with bone metastases","volume":"9","author":"Gonnelli","year":"1995","journal-title":"Clinical Drug Investigation"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0017|cit17","first-page":"121","article-title":"Adjuvant therapy with thymic factors in solid tumours","volume-title":"Thymic Hormones in Oncology","author":"Guzman Machado","year":"1988"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0018|cit18","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1007\/BF03257412","article-title":"Immunological and clinical effects of thymostimulin in patients with locally advanced non-small-cell lung cancer treated with combined chemoradiotherapy","volume":"7","author":"Iaffaioli","year":"1994","journal-title":"Drug Investigation"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0019|cit19","first-page":"309","article-title":"Clinical and immunological evaluation in non-resectable lung cancer patients treated with thymostimulin","volume":"16","author":"Luzi","year":"1984","journal-title":"Serono Symposia Publications"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0020|cit20","first-page":"193","article-title":"Effects of thymostimulin on chemotherapy-induced toxicity and long-term survival in small cell lung cancer patients","volume":"9","author":"Macchiarini","year":"1989","journal-title":"Anticancer Research"},{"issue":"18S","key":"10.1002\/14651858.CD003993.pub3-BIB0021|cit21","doi-asserted-by":"crossref","first-page":"8535","DOI":"10.1200\/jco.2007.25.18_suppl.8535","article-title":"A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results","volume":"25","author":"Camerini","year":"2007","journal-title":"Journal of Clinical Oncology"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0022|cit22","unstructured":"Camerini R Mackiewicz A Testori A Trefzer U Jassem J Ferraresi V A large first-line, randomized, dose-finding, phase II study on thymosin-alpha 1 (T-alpha 1) plus dacarbazine (DTIC) with or without interferon-alpha (IFN-alpha) compared to DTIC plus IFN-alpha in stage IV melanoma. Tumor response and survival results Powerpoint presentation ASCO Annual Meeting"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0023|cit23","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1200\/JCO.2009.25.5208","article-title":"Large randomized study of thymosin {alpha} 1, interferon alfa, or both in combination with dacarbazine in patients with metastatic melanoma","volume":"[Epub ahead of","author":"Maio","year":"2010","journal-title":"Journal of Clinical Oncology"},{"issue":"12","key":"10.1002\/14651858.CD003993.pub3-BIB0024|cit24","first-page":"513","article-title":"[Results of a controlled clinical protocol in the treatment of patients with operable breast carcinoma with positive axillary lymph nodes. Comparison of a chemotherapeutic regimen with a chemo-immunotherapeutic regimen]","volume":"79","author":"Mantovani","year":"1988","journal-title":"Recenti Progressi in Medicina"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0025|cit25","first-page":"617","article-title":"High-dose folinic acid (FA) and fluorouracil (FU) plus or minus thymostimulin (TS) for treatment of metastatic colorectal cancer: results of a randomized multicenter clinical trial","volume":"14","author":"Mustacchi","year":"1994","journal-title":"Anticancer Research"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0026|cit26","doi-asserted-by":"crossref","unstructured":"Pavesi L Fluorouracil (F), with and without high-dose folinic acid (HDFA) plus epirubicin (E) and cyclophosphamide (C): FEC versus HDFA-FEC plus or minus thymostimulin (TS) in metastatic breast cancer: results of a multicenter study European Journal of Cancer 1993 77","DOI":"10.1016\/0959-8049(93)91025-G"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0027|cit27","first-page":"185","article-title":"[MACC plus Thymostimulin (TP-1 Serono) therapy of small cell bronchogenic carcinoma. Clinico-immunologic evaluation of the results of a randomized trial]","volume":"31","author":"Salvati","year":"1984","journal-title":"Giornale Italiano di Chemiotherapia"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0028|cit28","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/0959-8049(95)00459-9","article-title":"A randomised study comparing granulocyte-colony stimulating factor (G-CSF) with G-CSF plus thymostimulin in the treatment of heamatological toxicity in patients with advanced breast cancer after high dose mitoxantrone therapy","volume":"32 A","author":"Sanchiz","year":"1996","journal-title":"European Journal of Cancer"},{"issue":"6","key":"10.1002\/14651858.CD003993.pub3-BIB0029|cit29","first-page":"1663","article-title":"Randomized trial of combined modality therapy with and without thymosin fraction V in the treatment of small cell lung cancer","volume":"48","author":"Scher","year":"1988","journal-title":"Cancer Research"},{"issue":"2","key":"10.1002\/14651858.CD003993.pub3-BIB0030|cit30","first-page":"147","article-title":"A randomized trail to evaluate the immunorestorative properties of synthetic thymosin-a in patients with lung cancer","volume":"4","author":"Schulof","year":"1985","journal-title":"Journal of Biological Response Modifiers"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0031|cit31","first-page":"257","article-title":"Biologic modifications of immunologic parameters in head and neck cancer patients with thymosin fraction V","volume-title":"Lymphokines and Thymic Hormones: their potential utilization in cancer therapeutics","author":"Wara","year":"1981"},{"issue":"II","key":"10.1002\/14651858.CD003993.pub3-BIB0032|cit32","first-page":"1043","article-title":"Postoperative adjuvante behandlung von patienten mit malignem melanom durch die thymusfaktor thymostimulin","volume":"34","author":"Azizi","year":"1984","journal-title":"Arzneimittelforschung"},{"issue":"3","key":"10.1002\/14651858.CD003993.pub3-BIB0033|cit33","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0090-1229(83)90098-3","article-title":"Thymostimulin therapy in melanoma patients: correlation of immunologic effects with clinical course","volume":"28","author":"Bernengo","year":"1983","journal-title":"Clinical Immunology and Immunopathology"},{"issue":"10","key":"10.1002\/14651858.CD003993.pub3-BIB0034|cit34","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/1097-0142(19831115)52:10<1841::AID-CNCR2820521014>3.0.CO;2-N","article-title":"The prognostic value of T-lymphocyte levels in malignant melanoma. A five-year follow-up","volume":"52","author":"Bernengo","year":"1983","journal-title":"Cancer"},{"issue":"11","key":"10.1002\/14651858.CD003993.pub3-BIB0035|cit35","first-page":"815","article-title":"[Evaluation of the effects of thymopentin on the incidence of leucopenia in patients treated with chemotherapy for breast carcinoma] Valutazione degli effetti di Timopentina sull`incidenza di leucopenia in pazienti trattate con chemioterapia per carcinom mammario","volume":"81","author":"Cartia","year":"1990","journal-title":"Minerva Medica"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0036|cit36","unstructured":"Chen J Huang F Zheng X Chen L Qin S Li G Thymosin alpha 1 positively alters quality of life in chemotherapy treated patients Proceedings American Society of Clinical Oncology 2000"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0037|cit37","first-page":"438","article-title":"T-lymphocyte subsets in cancer patients undergoing radiotherapy and their recovery after thymostimulin treatment. A cooperative study","volume":"18","author":"Maria","year":"1993","journal-title":"RAYS"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0038|cit38","first-page":"611","article-title":"[Immunologic study on patients with head and neck cancer treated with thymopentin associated with surgery, chemotherapy and radiotherapy]","volume":"14","author":"Denaro","year":"1994","journal-title":"Acta Otorhinolaryngologica Italica"},{"issue":"2","key":"10.1002\/14651858.CD003993.pub3-BIB0039|cit39","first-page":"201","article-title":"Cooperative randomized studies on the treatment of adult acute leukemia in Poland. A comparison of two remission induction regimes and two maintenance regimes for AML","volume":"111","author":"Holowiecki","year":"1984","journal-title":"Folia Haematologica"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0040|cit40","first-page":"69","article-title":"Effect of thymic extract \"thymostimulin\" on the incidence of infections and myelotoxicity during adjuvant chemotherapy for breast cancer","volume":"12","author":"Iaffaioli","year":"1988","journal-title":"Thymus"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0041|cit41","unstructured":"Kreuser ED [Randomised, double-blind trial to compare low-molecular thymic peptides, 5-fluorouracil and folic acid with placebo, 5-fluorouracil and folic acid in patients with metastasised colorectal cancer] Internet (\"This trial was identified via internet databases. In this multicenter study patients were randomised to receive thymuvocal or placebo. The pharmaceutical company (DR Schmidt) supposed to be in charge of did not provide information about this study\".) 1998"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0042|cit42","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00199853","article-title":"A randomized trial to evaluate the immunorestorative properties of thymostimulin in patients with Hodgkin`s disease in complete remission","volume":"26","author":"Liberati","year":"1998","journal-title":"Cancer Immunology, Immunotherapy"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0043|cit43","first-page":"8","article-title":"[The immunological assessment of a combined therapeutic approach (chemo- + radiotherapy +\/- surgery) including immunotherapy in neoplasms of the head and neck area at an advanced stage]","volume":"86","author":"Mantovani","year":"1995","journal-title":"Recenti Progressi in Medicina"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0044|cit44","first-page":"115","article-title":"[Results of a prospective randomised study on the immunologic effects of the xenogenic organ lysates Ney Tumorin-Sol and Neythymun compared to placebo]","volume":"35, 26A","author":"Migeod","year":"1985","journal-title":"Therapiewoche"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0045|cit45","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/cdli.2.4.503-505.1995","article-title":"Immunomodulatory effects of alpha interferon and thymostimulin in patients with neoplasias","volume":"2","author":"Munno","year":"1995","journal-title":"Clinical and Diagnostic Laboratory Immunology"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0046|cit46","unstructured":"Quang-Xing Ni Fu DI Yu XJ Xu J Hua JM Chen W Efficacy of thymalfasin on cellular immune function and chemotherapy induced toxicity in pancreatic cancer Proceedings American Society of Clinical Oncology 2001"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0047|cit47","first-page":"45","article-title":"The effect of the thymic factor thymostimulin on survival rate, immune function and resistance to infection in experimental and clinical cancer","volume-title":"Thymic Hormones in Oncology","author":"Shoham","year":"1988"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0048|cit48","first-page":"172","article-title":"Effect of immunostimulating therapy on the immunocompetent system in breast carcinoma","volume":"34","author":"Surico","year":"1992","journal-title":"Panminerva Medica"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0049|cit49","first-page":"51","article-title":"Uso di un farmaco immunomodulatore nella prevenzione della comparsadi episodi infettivi a carico delle vie urinarie in pazienti affette da neoplasie ginecologiche e sottoposte a ciclo TCT","volume":"78 Suppl 6","author":"Tetti","year":"1987","journal-title":"Recenti Progressi in Medicina"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0050|cit50","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/1471-2407-10-457","article-title":"Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial","volume":"10","author":"Dollinger","year":"2010","journal-title":"BMC Cancer"},{"issue":"5","key":"10.1002\/14651858.CD003993.pub3-BIB0051|cit51","first-page":"698","article-title":"Thymosin alpha1. SciClone Pharmaceuticals","volume":"3","author":"Billich","year":"2002","journal-title":"Current Opinion in Investigational Drugs"},{"issue":"4","key":"10.1002\/14651858.CD003993.pub3-BIB0052|cit52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0192-0561(99)00084-3","article-title":"Review of thymic hormones in cancer diagnosis and treatment","volume":"22","author":"Bodey","year":"2000","journal-title":"International Journal of Immunopharmacology"},{"issue":"22","key":"10.1002\/14651858.CD003993.pub3-BIB0053|cit53","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1093\/jnci\/djg100","article-title":"Role of thymosin beta4 in tumor metastasis and angiogenesis","volume":"95","author":"Cha","year":"2003","journal-title":"Journal of the National Cancer Institute"},{"issue":"11","key":"10.1002\/14651858.CD003993.pub3-BIB0054|cit54","first-page":"1787","article-title":"Thymosin in cancer patients: in vitro effects and correlations with clinical response to thymosin immunotherapy","volume":"62","author":"Chretien","year":"1978","journal-title":"Cancer Treatment Reports"},{"issue":"1","key":"10.1002\/14651858.CD003993.pub3-BIB0055|cit55","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1002\/1097-0142(197707)40:1<14::AID-CNCR2820400105>3.0.CO;2-O","article-title":"The effect of thymosin on patients with disseminated malignancies. A phase I study","volume":"40","author":"Costanzi","year":"1977","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0056|cit56","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) - Version 4.0 http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/About.html"},{"issue":"11","key":"10.1002\/14651858.CD003993.pub3-BIB0057|cit57","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1038\/ni1102-991","article-title":"Cancer immunoediting: from immunosurveillance to tumor escape","volume":"3","author":"Dunn","year":"2002","journal-title":"Nature Immunology"},{"issue":"4","key":"10.1002\/14651858.CD003993.pub3-BIB0058|cit58","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1016\/S0959-8049(96)00475-3","article-title":"Thymus therapy for cancer? A criteria-based, systematic review [see comments]","volume":"33","author":"Ernst","year":"1997","journal-title":"European Journal of Cancer"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0059|cit59","first-page":"39","article-title":"Pharmacological and biological properties of a calf thymus extract (TP-1)","volume":"3","author":"Falchetti","year":"1977","journal-title":"Drugs Under Experimental and Clinical Research"},{"issue":"3","key":"10.1002\/14651858.CD003993.pub3-BIB0060|cit60","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1073\/pnas.56.3.1010","article-title":"Preparation, assay, and partial purification of a thymic lymphocytopoietic factor (thymosin)","volume":"56","author":"Goldstein","year":"1966","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1002\/14651858.CD003993.pub3-BIB0061|cit61","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1073\/pnas.74.2.725","article-title":"Thymosin alpha1: isolation and sequence analysis of an immunologically active thymic polypeptide","volume":"74","author":"Goldstein","year":"1977","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"4399","key":"10.1002\/14651858.CD003993.pub3-BIB0062|cit62","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1126\/science.451537","article-title":"A synthetic pentapeptide with biological activity characteristic of the thymic hormone thymopoietin","volume":"204","author":"Goldstein","year":"1979","journal-title":"Science"},{"issue":"5","key":"10.1002\/14651858.CD003993.pub3-BIB0063|cit63","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1517\/14712590902911412","article-title":"From lab to bedside: emerging clinical applications of thymosin \u00e01","volume":"9","author":"Goldstein","year":"2009","journal-title":"Expert Opinion on Biological Therapy"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0064|cit64","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1055\/s-2007-1024099","article-title":"Anwendung alternativmedizinischer methoden durch onkologische patienten","volume":"123","author":"Grothey","year":"1998","journal-title":"Deutsche Medizinische Wochenschrift"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0065|cit65","first-page":"2","article-title":"The thymosins prothymosin \u00e0, parathymosin, and \u00e1-thymosins: structure and function","volume-title":"Vitamins and Hormones","author":"Hannappel","year":"2003"},{"issue":"18","key":"10.1002\/14651858.CD003993.pub3-BIB0066|cit66","first-page":"2092","article-title":"A new study of patients with cancer in Umea alternative medicine is no alternative","volume":"95","author":"Hardell","year":"1998","journal-title":"Lakartidningen"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0067|cit67","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.2 [updated September 2009]","volume":"available from","author":"Higgins","year":"2009"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0068|cit68","first-page":"Chapter 22","article-title":"Essential medical statistics","volume-title":"Essential medical statistics","author":"Kirkwood","year":"2003"},{"issue":"1","key":"10.1002\/14651858.CD003993.pub3-BIB0069|cit69","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/S0301-2115(98)00226-7","article-title":"Self-concept, body image, and use of unconventional therapies in patients with gynaecological malignancies in the state of complete remission and recurrence","volume":"82","author":"Kullmer","year":"1999","journal-title":"European Journal of Obstetrics, Gynecology, and Reproductive Biology"},{"issue":"1","key":"10.1002\/14651858.CD003993.pub3-BIB0070|cit70","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1002\/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6","article-title":"Reporting Results of Cancer Treatment","volume":"47","author":"Miller","year":"1981","journal-title":"Cancer"},{"key":"10.1002\/14651858.CD003993.pub3-BIB0071|cit71","first-page":"267","article-title":"Use of alternative \/ complementary therapy in breast cancer patients - a psychological perspective","volume":"9","author":"Moschen","year":"2001","journal-title":"Supportive Care in Cancer"},{"issue":"1","key":"10.1002\/14651858.CD003993.pub3-BIB0072|cit72","first-page":"51","article-title":"Pharmacokinetics of thymosin alpha1 after subcutaneous injection of three different formulations in healthy volunteers","volume":"37","author":"Rost","year":"1999","journal-title":"International Journal of Clinical Pharmacology and Therapeutics"},{"issue":"4","key":"10.1002\/14651858.CD003993.pub3-BIB0073|cit73","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/0092-8674(75)90055-0","article-title":"Chemical synthesis of a peptide fragment of thymopoietin II that induces selective T cell differentiation","volume":"5","author":"Schlesinger","year":"1975","journal-title":"Cell"},{"issue":"4","key":"10.1002\/14651858.CD003993.pub3-BIB0074|cit74","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S1040-8428(85)80035-4","article-title":"Thymic peptide hormones: basic properties and clinical applications in cancer","volume":"3","author":"Schulof","year":"1985","journal-title":"Critical Reviews in Oncology\/Hematology"},{"issue":"2","key":"10.1002\/14651858.CD003993.pub3-BIB0075|cit75","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1006\/gyno.2000.5987","article-title":"How frequently do female patients with gynecological cancers use unconventional cancer therapies?","volume":"79","author":"Sehouli","year":"2000","journal-title":"Gynecologic Oncology"},{"issue":"2","key":"10.1002\/14651858.CD003993.pub3-BIB0076|cit76","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/S0096-5588(20)31606-8","article-title":"Tumors of the thymus","volume":"20","author":"Seybold","year":"1950","journal-title":"Journal of Thoracic Surgery"},{"issue":"3","key":"10.1002\/14651858.CD003993.pub3-BIB0077|cit77","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1007\/BF02786456","article-title":"Thymopentin and splenopentin as immunomodulators. Current status","volume":"17","author":"Singh","year":"1998","journal-title":"Immunologic Research"},{"issue":"3","key":"10.1002\/14651858.CD003993.pub3-BIB0078|cit78","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1001\/archderm.1997.03890390054007","article-title":"Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma","volume":"133","author":"Soellner","year":"1997","journal-title":"Archives of Dermatology"},{"issue":"3","key":"10.1002\/14651858.CD003993.pub3-BIB0079|cit79","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada","volume":"92","author":"Therasse","year":"2000","journal-title":"Journal of the National Cancer Institute"}],"container-title":["Cochrane Database of Systematic Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1002\/14651858.CD003993.pub3\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,25]],"date-time":"2025-12-25T20:01:27Z","timestamp":1766692887000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1002\/14651858.CD003993.pub3"}},"subtitle":[],"editor":[{"name":"Cochrane Gynaecological, Neuro-oncology and Orphan Cancer Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2011,2,16]]},"references-count":79,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,5]]}},"URL":"https:\/\/doi.org\/10.1002\/14651858.cd003993.pub3","relation":{},"ISSN":["1465-1858"],"issn-type":[{"value":"1465-1858","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,2,16]]}}}